The previous reports showed that TP53 mutation was associated with anthracycline sensitivity [14,15,16,17], while some indicated that TP53 mutation conferred anthracycline resistance to breast cancer patients and resulted in a poor prognosis [21,22,23,24]. The gene discussed is TP53; the disease is breast carcinoma.